睿知中国疾病研究地图
候选清单0

上海海军军医大学

海军军医大学第三附属医院(东方肝胆外科医院)

Eastern Hepatobiliary Surgery Hospital

在本站收录的 53 种疾病中,这家医院列在其中 6 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

海军军医大学第三附属医院(东方肝胆外科医院)的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肝细胞癌Hepatocellular carcinoma214 篇牵头论文牵头 4 项开放试验
  2. 胃癌Stomach cancer6 篇牵头论文
  3. 骨肉瘤Osteosarcoma4 篇牵头论文
  4. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  5. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  6. 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 214 篇,占 1.5%。

牵头论文
214
2021–2025 年
牵头试验
55
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 444420212022: 484820222023: 414120232024: 404020242025: 37372025

上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 8

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
    分期
    I/II期
    开始
    2025-07
    登记号
    NCT06902389

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:海军军医大学第三附属医院(东方肝胆外科医院)上海

  2. 正在招募
    The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
    分期
    II/III期
    开始
    2025-10
    登记号
    NCT07285850

    年龄 18 岁 至 未注明(登记的条件)

    牵头:海军军医大学第三附属医院(东方肝胆外科医院)上海

  3. 即将招募
    A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer
    分期
    不分期
    开始
    2026-01
    登记号
    NCT07337031

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:海军军医大学第三附属医院(东方肝胆外科医院)上海

  4. 即将招募
    Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
    分期
    II期
    开始
    2026-01
    登记号
    NCT07363356

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:海军军医大学第三附属医院(东方肝胆外科医院)上海

  5. 正在招募
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    分期
    未注明
    开始
    2025-09
    登记号
    NCT07170345

    年龄 18 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南宁、广州、成都、沈阳、温州、珠海、福州、郑州

  6. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  7. 即将招募
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    分期
    未注明
    开始
    2025-08
    登记号
    NCT07100236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、合肥、广州、杭州、温州、福州、郑州

  8. 邀请入组
    Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
    分期
    未注明
    开始
    2024-08
    登记号
    NCT06712017

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、北京、广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后手术与肝移植影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科影像/核医学科病理/检验科肿瘤内科
牵头的论文214
  1. LGR5/mTORC2 axis regulates cellular metabolic plasticity to maintain tumorigenesis in hepatocellular carcinoma.2026Cancer letters
  2. Novel dual-targeted modified polyester albumin nano-carriers enhance the efficacy of hepatocellular carcinoma outcomes after encapsulating lenvatinib.2026Journal of biomaterials applications
  3. RAC1 directly phosphorylates both PKM2 and FBP1 to promote radioresistance in hepatocellular carcinoma.2026Molecular therapy : the journal of the American Society of Gene Therapy
  4. Deciphering the significance of tumor necrosis and developing a grading system in combined hepatocellular-cholangiocarcinoma: A multicenter pathological study.2026Pathology, research and practice
  5. Next-Generation Flexible Embolic Systems: Targeted Transarterial Chemoembolization Strategies for Hepatocellular Carcinoma.2025Advanced materials (Deerfield Beach, Fla.)
  6. Hydrogen-Bonded Organic Framework Nanoscintillators for X-Ray-Induced Photodynamic Therapy in Hepatocellular Carcinoma.2025Advanced materials (Deerfield Beach, Fla.)
  7. Cost-Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  8. Development models to predict complication and prognosis following liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension.2025American journal of surgery
  9. Development and Validation of an Individualized Prediction Model for Postoperative Late Recurrence After Hepatectomy for Hepatocellular Carcinoma (POLAR-HCC): A Multicenter Study.2025Annals of surgical oncology
  10. Statistical Cure After Hepatectomy for Hepatitis B Virus-Associated Hepatocellular Carcinoma: A Risk-Stratification Model.2025Annals of surgical oncology
  11. α-Fetoprotein model versus Milan criteria in predicting outcomes after hepatic resection for hepatocellular carcinoma: multicentre study.2025BJS open免费全文
  12. The role of prognostic nutrition index in the prognosis of patients with advanced hepatocellular carcinoma who received first-line therapy.2025BMC cancer免费全文
  13. Radiofrequency ablation versus stereotactic body radiotherapy for recurrent hepatocellular carcinoma: a multicenter, propensity score matching analysis.2025BMC cancer免费全文
  14. Integrated ultrasound radiomics and clinical data to predict PD-1 blockade efficacy in unresectable hepatocellular carcinoma.2025BMC gastroenterology免费全文
  15. Repeat laparoscopic hepatectomy versus radiofrequency ablation for recurrent hepatocellular carcinoma: A multicenter, propensity score matching analysis.2025Bioscience trends
  16. Risk stratification model for predicting distant metastasis after hepatectomy for hepatocellular carcinoma: A multi-institutional analysis.2025Bioscience trends
  17. Intranuclear paraspeckle-circular RNA TACC3 assembly forms RNA-DNA hybrids to facilitate MASH-related hepatocellular carcinoma growth in an m6A-dependent manner.2025Cancer communications (London, England)免费全文
  18. Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma.2025Cancer immunology, immunotherapy : CII免费全文
  19. Drug resistance in TKI therapy for hepatocellular carcinoma: Mechanisms and strategies.2025Cancer letters
  20. Comparison of clinical characteristics and outcomes in patients with hepatocellular carcinoma based on serum alpha-fetoprotein status.2025European journal of gastroenterology & hepatology
  21. CCDC137/DGCR8 axis promotes aerobic glycolysis in hepatocellular carcinoma via activation of the AKT/mTOR signaling pathway.2025European journal of medical research免费全文
  22. Prediction models after hepatectomy for hepatocellular carcinoma-based ultrasonic radiomics: an observational study.2025European journal of medical research免费全文
  23. Trajectories of postoperative hepatitis B virus (HBV) DNA and HBV-related hepatocellular carcinoma outcomes.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  24. Heterogeneity in prognosis for early-stage hepatocellular carcinoma after hepatectomy: A multicenter analysis of 4,623 patients across five major staging systems.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  25. Preoperative ASAP score predicts recurrence and survival following curative hepatic resection for hepatitis B virus-related hepatocellular carcinoma: A multicenter cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  26. Benefits of entecavir therapy in HBV-related hepatocellular carcinoma patients with compensated cirrhosis after hepatectomy: A ten-year retrospective cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  27. Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.2025Frontiers in immunology免费全文
  28. Impact of compliance to postoperative regular follow-up on long-term prognosis after curative resection for hepatocellular carcinoma: A multicenter analysis.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  29. HBcrAg is associated with prognosis of hepatitis B virus-related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy.2025International journal of cancer
  30. Perineural invasion as a prognostic determinant in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  31. Tumor biology characteristics score based on alpha-fetoprotein and protein induced by vitamin K absence or antagonist II as a predictor for recurrence and survival after curative resection for hepatocellular carcinoma: a multicenter cohort 2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  32. Liver ischemia-reperfusion promotes tumor metastasis via neutrophil-endothelial interactions: targeting ICAM1 to prevent metastatic recurrence.2025Journal of translational medicine免费全文
  33. microRNA-2117 Negatively Regulates Liver Cancer Stem Cells Expansion and Chemoresistance Via Targeting SOX2.2025Molecular carcinogenesis免费全文
  34. [Expression of Concern] Inhibition of tumorigenesis and invasion of hepatocellular carcinoma by siRNA‑mediated silencing of the livin gene.2025Molecular medicine reports免费全文
  35. CYB5D2 inhibits the malignant progression of hepatocellular carcinoma by inhibiting TGF-β expression and epithelial-mesenchymal transition.2025Oncology research免费全文
  36. Effect of Early Tumor Shrinkage and Depth of Response on the Clinical Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization and Lenvatinib plus PD-1 Inhibitors.2025Oncology research and treatment
  37. Ultrasounic-radiomics models for predicting the response to Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma.2025PloS one免费全文
  38. Stereotactic body radiotherapy versus laparoscopic liver resection for single hepatocellular carcinoma ≤ 5 cm: a retrospective, multicenter, cohort study.2025Scientific reports免费全文
  39. Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial.2025Signal transduction and targeted therapy免费全文
  40. Attenuation trend of alpha-fetoprotein predicts postoperative prognosis in alpha-fetoprotein-positive hepatocellular carcinoma patients.2025Surgery
  41. Postoperative adjuvant transarterial chemoembolization prolongs overall survival in alpha-fetoprotein-negative hepatocellular carcinoma with bile duct tumor thrombosis: a long-term retrospective cohort study.2025World journal of surgical oncology免费全文
  42. Preoperative evaluation of MRI features and inflammatory biomarkers in predicting microvascular invasion of combined hepatocellular cholangiocarcinoma.2024Abdominal radiology (New York)免费全文
  43. Optimizing predictions: improved performance of preoperative gadobenate-enhanced MRI hepatobiliary phase features in predicting vessels encapsulating tumor clusters in hepatocellular carcinoma-a multicenter study.2024Abdominal radiology (New York)
  44. Preoperative Three-Dimensional Morphological Tumor Features Predict Microvascular Invasion in Hepatocellular Carcinoma.2024Academic radiology
  45. Hydrogel Crosslinked with Nanoparticles for Prevention of Surgical Hemorrhage and Recurrence of Hepatocellular Carcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  46. Development and validation of prealbumin-bilirubin score (preALBI score) for predicting long-term survival after hepatectomy for hepatocellular carcinoma: A multicenter analysis versus ALBI score.2024American journal of surgery
  47. Association of preoperative frailty with short- and long-term outcomes after hepatic resection for elderly patients with hepatocellular carcinoma: multicentre analysis.2024BJS open免费全文
  48. F13B regulates angiogenesis and tumor progression in hepatocellular carcinoma via the HIF-1α/VEGF pathway.2024Biomolecules & biomedicine免费全文
  49. Transcription factor ASCL1 targets SLC6A13 to inhibit the progression of hepatocellular carcinoma via the glycine-inflammasome signaling.2024Biomolecules & biomedicine免费全文
  50. METTL3-Mediated m6A Modification of FMRP Drives Hepatocellular Carcinoma Progression and Indicates Poor Prognosis.2024Cancer biotherapy & radiopharmaceuticals
  51. Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma.2024Cancer immunology, immunotherapy : CII免费全文
  52. Spatial multimodal analysis revealed tertiary lymphoid structures as a risk stratification indicator in combined hepatocellular-cholangiocarcinoma.2024Cancer letters
  53. Identification of SPP1+ macrophages in promoting cancer stemness via vitronectin and CCL15 signals crosstalk in liver cancer.2024Cancer letters
  54. Expression Characteristics, Immune Signature, and Prognostic Value of the SOCS Family Identified by Multiomics Integrative Analysis in Liver Cancer.2024Cancer reports (Hoboken, N.J.)免费全文
  55. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities.2024Cancer science免费全文
  56. miR-4461 inhibits liver cancer stem cells expansion and chemoresistance via regulating SIRT1.2024Carcinogenesis
  57. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.2024Cell death & disease免费全文
  58. Baicalein Targets MAPK9 to Induce Apoptosis of Hepatocellular Carcinoma Cells.2024Chemical biology & drug design
  59. Cell-free DNA testing for early hepatocellular carcinoma surveillance.2024EBioMedicine免费全文
  60. Early prediction of microvascular invasion (MVI) occurrence in hepatocellular carcinoma (HCC) by 18F-FDG PET/CT and laboratory data.2024European journal of medical research免费全文
  61. Spatial multiomics reveals a subpopulation of fibroblasts associated with cancer stemness in human hepatocellular carcinoma.2024Genome medicine免费全文
  62. Nuclear translocation of plasma membrane protein ADCY7 potentiates T cell-mediated antitumour immunity in HCC.2024Gut免费全文
  63. B. thetaiotaomicron-derived acetic acid modulate immune microenvironment and tumor growth in hepatocellular carcinoma.2024Gut microbes免费全文
  64. Preoperative frailty as a key predictor of short- and long-term outcomes among octogenarians undergoing hepatectomy for hepatocellular carcinoma: a multicenter comprehensive analysis.2024HPB : the official journal of the International Hepato Pancreato Biliary Association
  65. A new scoring system for predicting the outcome of hepatocellular carcinoma patients without microvascular invasion-a large-scale multicentre study.2024HPB : the official journal of the International Hepato Pancreato Biliary Association
  66. Collagen in hepatocellular carcinoma: A novel biomarker and therapeutic target.2024Hepatology communications免费全文
  67. Association of diabetes mellitus with long-term prognosis after ablation therapy for patients with hepatocellular carcinoma: A single-center cohort study.2024Journal of cancer research and therapeutics
  68. Efficacy of microwave ablation with parallel acupuncture guided by ultrasound in treating single hepatocellular carcinoma in high-risk areas: A retrospective analysis of 155 patients.2024Journal of cancer research and therapeutics
  69. A new chemotherapy strategy for advanced hepatocellular carcinoma with exrahepatic metastasis: predictors of long-term survival.2024Journal of chemotherapy (Florence, Italy)
  70. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases.2024Medicine免费全文
  71. Deep whole-genome analysis of 494 hepatocellular carcinomas.2024Nature
  72. Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial.2024Nature communications免费全文
  73. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.2024Nature medicineRCT
  74. Clinical significance of small nuclear ribonucleoprotein U1 subunit 70 in patients with hepatocellular carcinoma.2024PeerJ免费全文
  75. lncRNA POLR2J4 Plays a Biomarker Role in Hepatitis B Virus-Related Hepatocellular Carcinoma Through Regulating miR-214-3p.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  76. Interleukin-17A educated hepatic stellate cells promote hepatocellular carcinoma occurrence through fibroblast activation protein expression.2024The journal of gene medicine
  77. Prognostic significance of postoperative serological incomplete conversion of AFP and PIVKA-II after hepatic resection for hepatocellular carcinoma: a multicenter analysis of 1755 patients.2024The oncologist免费全文
  78. Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody.2024The oncologist免费全文
  79. Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study.2024The oncologist免费全文
  80. Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma.2024Theranostics免费全文
  81. Predicting hepatocellular carcinoma: A new non-invasive model based on shear wave elastography.2024World journal of gastroenterology免费全文
  82. TWEAK Signaling-Induced ID1 Expression Drives Malignant Transformation of Hepatic Progenitor Cells During Hepatocarcinogenesis.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  83. Genomic landscape of Chinese patients with hepatocellular carcinoma using next-generation sequencing and its association with the prognosis.2023Annals of hepatology
  84. ASO Author Reflections: Effect of Preoperative Metabolic Syndrome for Patients with Hepatocellular Carcinoma.2023Annals of surgical oncology
  85. Association of Concurrent Metabolic Syndrome with Long-term Oncological Prognosis Following Liver Resection for Hepatocellular Carcinoma Among Patients with Chronic Hepatitis B Virus Infection: A Multicenter Study of 1753 Patients.2023Annals of surgical oncology
  86. A nomogram for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma based on spleen-volume-to-platelet ratio.2023Asian journal of surgery
  87. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.2023BMC cancer免费全文
  88. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.2023Briefings in bioinformatics免费全文
  89. Serologic status and safety of inactivated Covid-19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection.2023Cancer communications (London, England)免费全文
  90. Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study.2023Cancer medicine免费全文
  91. A reasonable identification of the early recurrence time based on microvascular invasion for hepatocellular carcinoma after R0 resection: A multicenter retrospective study.2023Cancer medicine免费全文
  92. Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment.2023Cellular & molecular immunology免费全文
  93. Phosphotriesterase-related protein as a novel prognostic predictor for hepatocellular carcinoma patients.2023Chinese clinical oncology
  94. Cidan Capsule in Combination with Adjuvant Transarterial Chemoembolization Reduces Recurrence Rate after Curative Resection of Hepatocellular Carcinoma: A Multicenter, Randomized Controlled Trial.2023Chinese journal of integrative medicineRCT
  95. Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences.2023Clinical and molecular hepatology免费全文
  96. Discovering the digital biomarker of hepatocellular carcinoma in serum with SERS-based biosensors and intelligence vision.2023Colloids and surfaces. B, Biointerfaces
  97. Prediction of microvascular invasion in combined hepatocellular-cholangiocarcinoma based on preoperative contrast-enhanced CT and clinical data.2023European journal of radiology
  98. Circular RNA cFAM210A, degradable by HBx, inhibits HCC tumorigenesis by suppressing YBX1 transactivation.2023Experimental & molecular medicine免费全文
  99. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.2023Frontiers in immunology免费全文
  100. Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma.2023Frontiers in immunology免费全文
  101. Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study.2023Frontiers in immunology免费全文
  102. Hypoxia-induced circRTN4IP1 promotes progression and glycolysis of hepatocellular carcinoma cells.2023Functional & integrative genomics
  103. Prospective validation of the Eastern Staging in predicting survival after surgical resection for patients with hepatocellular carcinoma: a multicenter study from China.2023HPB : the official journal of the International Hepato Pancreato Biliary Association
  104. Development of preoperative prognostic models including radiological features for survival of singular nodular HCC patients.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  105. Laparoscopic and open liver resection for hepatocellular carcinoma with type 2 diabetes mellitus: multicenter propensity score-matched study.2023Hepatology international
  106. Structural changes and anti-hepatocellular carcinoma activity of interferon-γ after interaction with sinensetin.2023International journal of biological macromolecules
  107. N6-Methyladenosine Modification of ANLN Enhances Hepatocellular Carcinoma Bone Metastasis.2023International journal of biological sciences免费全文
  108. Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection.2023JAMA network open免费全文
  109. Mechanisms of portal vein tumour thrombus formation and development in patients with hepatocellular carcinoma.2023Journal of cellular and molecular medicine免费全文
  110. The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis.2023Journal of hematology & oncology免费全文
  111. Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells.2023Journal of hepatology
  112. Orthogonally Engineered Albumin with Attenuated Macrophage Phagocytosis for the Targeted Visualization and Phototherapy of Liver Cancer.2023Journal of the American Chemical Society
  113. A new and rare type of hepatocellular carcinoma: Survival and gene analysis of portal vein tumour thrombus-type hepatocellular carcinoma.2023Pathology, research and practice
  114. High-throughput sequencing approach for the identification of lncRNA biomarkers in hepatocellular carcinoma and revealing the effect of ZFAS1/miR-150-5p on hepatocellular carcinoma progression.2023PeerJ免费全文
  115. Immune index: A gene and cell prognostic signature for immunotherapy response prediction in hepatocellular carcinoma.2023Pharmacological research
  116. Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.2023Signal transduction and targeted therapyRCT免费全文
  117. Preoperative and Prognostic Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Review Based on Artificial Intelligence.2023Technology in cancer research & treatment免费全文
  118. Neutrophil-to-Lymphocyte Ratio and Early Tumor Shrinkage as Predictive Biomarkers in Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib, PD-1 Inhibitors, in Combination With TACE.2023Technology in cancer research & treatment免费全文
  119. GPNMB+ Gal-3+ hepatic parenchymal cells promote immunosuppression and hepatocellular carcinogenesis.2023The EMBO journal免费全文
  120. The Comparison of Surgical Margins and Type of Hepatic Resection for Hepatocellular Carcinoma With Microvascular Invasion.2023The oncologist免费全文
  121. Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE.2023The oncologist免费全文
  122. Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma.2023World journal of surgical oncology免费全文
  123. Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells.2022Acta pharmacologica Sinica免费全文
  124. Post-hepatectomy liver failure prediction and prevention: Development of a nomogram containing postoperative anticoagulants as a risk factor.2022Annals of hepatology
  125. Evaluation of nuclear PGAM2 value in hepatocellular carcinoma prognosis.2022Anti-cancer drugs免费全文
  126. Long-term oncological prognosis after curative-intent liver resection for hepatocellular carcinoma in the young versus the elderly: multicentre propensity score-matching study.2022BJS open免费全文
  127. Laparoscopic right hemihepatectomy following a novel optimized portal vein embolization: a video case report.2022BMC gastroenterology免费全文
  128. Preoperative diagnosis and prediction of microvascular invasion in hepatocellularcarcinoma by ultrasound elastography.2022BMC medical imaging免费全文
  129. Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol.2022BMJ open免费全文
  130. DANCR deletion retards the initiation and progression of hepatocellular carcinoma based on gene knockout and patient-derived xenograft in situ hepatoma mice model.2022Cancer letters
  131. Gankyrin and TIGAR cooperatively accelerate glucose metabolism toward the PPP and TCA cycle in hepatocellular carcinoma.2022Cancer science免费全文
  132. DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334.2022Cell death & disease免费全文
  133. Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis.2022Cell death & disease免费全文
  134. A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study.2022Chinese medical journal免费全文
  135. Novel transketolase inhibitor oroxylin A suppresses the non-oxidative pentose phosphate pathway and hepatocellular carcinoma tumour growth in mice and patient-derived organoids.2022Clinical and translational medicine免费全文
  136. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.2022Clinics and research in hepatology and gastroenterology
  137. Response to letter entitled: Re: 'Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial'.2022European journal of cancer (Oxford, England : 1990)
  138. Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial.2022European journal of cancer (Oxford, England : 1990)RCT
  139. A novel classification in predicting prognosis and guiding postoperative management after R0 liver resection for patients with hepatocellular carcinoma and microvascular invasion.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  140. Impact of concurrent splenectomy and esophagogastric devascularization on surgical outcomes of partial hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: A multicenter propensity score matc2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  141. Association of type 2 diabetes mellitus with incidences of microvascular invasion and survival outcomes in hepatitis B virus-related hepatocellular carcinoma after liver resection: A multicenter study.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  142. Reply to: Letter to the Editor "Association of type 2 diabetes mellitus with incidences of microvascular invasion and survival outcomes in hepatitis B virus-related hepatocellular carcinoma after liver resection: A multicenter study".2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  143. Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial.2022Future oncology (London, England)
  144. Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China.2022HPB : the official journal of the International Hepato Pancreato Biliary Association
  145. Postoperative adjuvant transarterial chemoembolization improves outcomes of hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis.2022HPB : the official journal of the International Hepato Pancreato Biliary Association
  146. Recurrence hazard rate in patients with hepatocellular carcinoma and bile duct tumor thrombus: a multicenter observational study.2022HPB : the official journal of the International Hepato Pancreato Biliary Association
  147. A stable and reliable animal model for hepatocellular carcinoma with portal vein tumor thrombus.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  148. Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial.2022Hepatology internationalRCT
  149. Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.2022Hepatology international免费全文
  150. A deep learning model with incorporation of microvascular invasion area as a factor in predicting prognosis of hepatocellular carcinoma after R0 hepatectomy.2022Hepatology international
  151. Perioperative and long-term survival outcomes of laparoscopic versus laparotomic hepatectomy for BCLC stages 0-A hepatocellular carcinoma patients associated with or without microvascular invasion: a multicenter, propensity score matching a2022Hepatology international
  152. Image-matching digital macro-slide-a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma.2022Hepatology international免费全文
  153. Association of Adjuvant Radiation Therapy With Long-Term Overall and Recurrence-Free Survival After Hepatectomy for Hepatocellular Carcinoma: A Multicenter Propensity-Matched Study.2022International journal of radiation oncology, biology, physics
  154. Development and validation of safety and efficacy-associated risk calculator for hepatocellular carcinoma in the elderly after resection (SEARCHER): A multi-institutional observational study.2022International journal of surgery (London, England)
  155. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study.2022International journal of surgery (London, England)
  156. Comparison of percutaneous microwave ablation with radiofrequency ablation for hepatocellular carcinoma adjacent to major vessels: A retrospective study.2022Journal of cancer research and therapeutics
  157. Immune-related lncRNA signature delineates an immune-excluded subtype of liver cancer with unfavorable clinical outcomes.2022Journal of clinical laboratory analysis免费全文
  158. Metabolome and transcriptome integration reveals metabolic profile of hepatocellular carcinoma.2022Journal of gastroenterology and hepatology
  159. A Web-Based Prediction Model for Estimating the Probability of Post-hepatectomy Major Complications in Patients with Hepatocellular Carcinoma: A Multicenter Study from a Hepatitis B Virus-Endemic Area.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  160. Screening of Hepatocellular Carcinoma Patients with High Risk of Early Recurrence After Radical Hepatectomy Using a Nomogram Model Based on the γ-Glutamyl Transpeptidase-to-Albumin Ratio.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractRCT
  161. Acute-Phase Serum Amyloid A May Predict Microvascular Invasion and Early Tumor Recurrence in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Liver Resection.2022Journal of investigative surgery : the official journal of the Academy of Surgical Research
  162. A Double Suspension Technique for Laparoscopic Isolated Caudate Lobectomy.2022Journal of laparoendoscopic & advanced surgical techniques. Part A
  163. Extracellular microparticles derived from hepatic progenitor cells deliver a death signal to hepatoma-initiating cells.2022Journal of nanobiotechnology免费全文
  164. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study.2022Liver international : official journal of the International Association for the Study of the Liver
  165. miR-2392 functions as tumour suppressor and inhibits malignant progression of hepatocellular carcinoma via directly targeting JAG2.2022Liver international : official journal of the International Association for the Study of the Liver
  166. Metabolomics-based classification reveals subtypes of hepatocellular carcinoma.2022Molecular carcinogenesis
  167. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevity免费全文
  168. The LINC00261/MiR105-5p/SELL axis is involved in dysfunction of B cell and is associated with overall survival in hepatocellular carcinoma.2022PeerJ免费全文
  169. Risk factors and long-term prognosis of beyond-Milan recurrence after hepatectomy for BCLC stage 0/A hepatocellular carcinoma: A large-scale multicenter study.2022Surgery
  170. Sparse logistic regression revealed the associations between HBV PreS quasispecies and hepatocellular carcinoma.2022Virology journal免费全文
  171. NET1 promotes HCC growth and metastasis in vitro and in vivo via activating the Akt signaling pathway.2021Aging免费全文
  172. TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma.2021Aging免费全文
  173. Association between preoperative prealbumin level and postoperative mortality and morbidity after hepatic resection for hepatocellular carcinoma: A multicenter study from a HBV-endemic area.2021American journal of surgery
  174. Influence of postoperative adjuvant transarterial chemoembolization on the prognosis of early-stage intrahepatic cholangiocarcinoma: a single center study.2021Annals of palliative medicine
  175. Preoperative Estimated Risk of Microvascular Invasion is Associated with Prognostic Differences Following Liver Resection Versus Radiofrequency Ablation for Early Hepatitis B Virus-Related Hepatocellular Carcinoma.2021Annals of surgical oncology
  176. miR-93 regulates liver tumor initiating cells expansion and predicts chemotherapeutic response of patients.2021Archives of biochemistry and biophysics
  177. Stabilization of snail maintains the sorafenib resistance of hepatocellular carcinoma cells.2021Archives of biochemistry and biophysics
  178. Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis.2021Bioengineered免费全文
  179. Clinical utility of serum biomarkers for hepatocellular carcinoma.2021Biomarkers in medicine
  180. Oncostatin M promotes hepatic progenitor cell activation and hepatocarcinogenesis via macrophage-derived tumor necrosis factor-α.2021Cancer letters
  181. The difference in prolonged continuous and intermittent Pringle maneuver during complex hepatectomy for hepatocellular carcinoma patients with chronic liver disease: A retrospective cohort study.2021Cancer medicine免费全文
  182. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis.2021Cancer medicine免费全文
  183. RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding.2021Cell death & disease免费全文
  184. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients.2021Cell research免费全文
  185. Incidence And Risk Factors Of Contrast Nephropathy After Tace In Patients With Liver Cancer And Chronic Kidney Disease.2021Clinical and investigative medicine. Medecine clinique et experimentale
  186. 4-phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR-α.2021Clinical and translational medicine免费全文
  187. The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients.2021Clinical cancer research : an official journal of the American Association for Cancer Research
  188. A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma.2021Clinics and research in hepatology and gastroenterology
  189. "Shared Decision Making Assistant": A Smartphone Application to Meet the Decision-Making Needs of Patients With Primary Liver Cancer.2021Computers, informatics, nursing : CIN
  190. Tumor cells derived-extracellular vesicles transfer miR-3129 to promote hepatocellular carcinoma metastasis by targeting TXNIP.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  191. Serum N-glycan fingerprint helps to discriminate intrahepatic cholangiocarcinoma from hepatocellular carcinoma.2021Electrophoresis
  192. TRIM56 suppresses the malignant development of hepatocellular carcinoma via targeting RBM24 and inactivating the Wnt signaling.2021European review for medical and pharmacological sciences
  193. The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing.2021Frontiers in immunology免费全文
  194. The CD68+ macrophages to CD8+ T-cell ratio is associated with clinical outcomes in hepatitis B virus (HBV)-related hepatocellular carcinoma.2021HPB : the official journal of the International Hepato Pancreato Biliary Association
  195. Postoperative adjuvant transcatheter arterial chemoembolization improves the prognosis of patients with huge hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  196. ATP-citrate lyase regulates stemness and metastasis in hepatocellular carcinoma via the Wnt/β-catenin signaling pathway.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  197. Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis.2021Hepatology (Baltimore, Md.)
  198. HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3.2021Hepatology (Baltimore, Md.)
  199. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.2021Hepatology international免费全文
  200. Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China.2021Hepatology international
  201. Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma.2021Hepatology international
  202. N-glycan fingerprint predicts alpha-fetoprotein negative hepatocellular carcinoma: A large-scale multicenter study.2021International journal of cancer
  203. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China.2021Journal of clinical laboratory analysis免费全文
  204. Thrombus-First Surgery for Hepatocellular Carcinoma with Bile Duct Tumor Thrombus.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  205. The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma.2021Journal of nanobiotechnology免费全文
  206. Loss of STAT5A promotes glucose metabolism and tumor growth through miRNA-23a-AKT signaling in hepatocellular carcinoma.2021Molecular oncology免费全文
  207. miR-369-3p serves as prognostic factor and regulates cancer progression of hepatocellular carcinoma.2021Personalized medicine
  208. Effect of PI3K/AKT/mTOR Signaling Pathway on Regulating and Controlling the Anti-Invasion and Metastasis of Hepatoma Cells by Bufalin.2021Recent patents on anti-cancer drug discovery
  209. Potent antitumor activity of a glutamyltransferase-derived peptide via an activation of oncosis pathway.2021Scientific reports免费全文
  210. An RNA-RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity.2021Signal transduction and targeted therapy免费全文
  211. SOX9-transactived long non-coding RNA NEAT1 promotes the self-renewal of liver cancer stem cells through PKA/Hippo signaling.2021Signal transduction and targeted therapy免费全文
  212. Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: A multicenter propensity score matching analysis.2021Surgery
  213. Using Quasispecies Patterns of Hepatitis B Virus to Predict Hepatocellular Carcinoma With Deep Sequencing and Machine Learning.2021The Journal of infectious diseases
  214. Extracellular-vesicles delivered tumor-specific sequential nanocatalysts can be used for MRI-informed nanocatalytic Therapy of hepatocellular carcinoma.2021Theranostics免费全文
中文论文(未计入)3
  1. [Systemic therapeutic strategies for hepatocellular carcinoma: current status and prospects].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Drug research and development and unmet needs for advanced-stage hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  3. [Combined hepatocellular-cholangiocarcinoma containing both large and small duct type cholangiocarcinoma: report of a case].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)73
  1. A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer即将招募NCT07337031牵头方不分期2026-01 启动
  2. Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer即将招募NCT07363356牵头方II期2026-01 启动
  3. The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD正在招募NCT07285850牵头方II/III期2025-10 启动
  4. A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma正在招募NCT06902389牵头方I/II期2025-07 启动
  5. Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma状态不明NCT05925413牵头方II期2023-04 启动
  6. Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma已完成NCT05540925牵头方2022-01 启动
  7. Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma状态不明NCT04386772牵头方不分期2020-05 启动
  8. Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma状态不明NCT04523467牵头方不分期2020-12 启动
  9. A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells状态不明NCT04521491牵头方不分期2020-12 启动
  10. Prospective Surveillance for Very Early Hepatocellular Carcinoma状态不明NCT03588442牵头方2018-07 启动
  11. Effect of Intraoperative Controlled Release 5-Fluorouracil Therapy on Recurrence in Hepatocellular Carcinoma Patients状态不明NCT02523053牵头方不分期2016-04 启动
  12. Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC已完成NCT03047603牵头方2016-05 启动
  13. Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI已完成NCT04891874牵头方不分期2015-08 启动
  14. The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma状态不明NCT02525965牵头方不分期2015-08 启动
  15. Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System状态不明NCT02525952牵头方不分期2015-10 启动
  16. Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma状态不明NCT02586285牵头方I期2015-06 启动
  17. Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma状态不明NCT02150317牵头方不分期2014-01 启动
  18. Postoperative Adjuvant TACE Treatment in CK18 Positive Patients已完成NCT02724345牵头方2013-01 启动
  19. Preoperative Pain Control in Liver Surgery Patients已完成NCT01923948牵头方不分期2013-05 启动
  20. The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related Gene已完成NCT01786980牵头方2012-10 启动
  21. Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology已完成NCT02727673牵头方2012-12 启动
  22. Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)已完成NCT01643447牵头方不分期2012-05 启动
  23. Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma已完成NCT02724436牵头方不分期2012-12 启动
  24. Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion已完成NCT02728219牵头方不分期2012-05 启动
  25. Targeted Internal Radiation Therapy in Advanced HCC Patients.已完成NCT02724267牵头方不分期2012-11 启动
  26. Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1已完成NCT02724358牵头方不分期2012-12 启动
  27. Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus已完成NCT02724475牵头方不分期2012-12 启动
  28. Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC已完成NCT02724332牵头方I期2012-11 启动
  29. Standard Treatments of Very-early Stage Hepatocellular Carcinoma已完成NCT02728193牵头方不分期2012-12 启动
  30. Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma状态不明NCT01860222牵头方不分期2011-01 启动
  31. Total Hemihepatic Vascular Exclusion in Hepatectomy in Hepatocellular Carcinoma Treatment已完成NCT00827047牵头方不分期2009-01 启动
  32. Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy已完成NCT00820339牵头方II/III期2009-01 启动
  33. A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection已完成NCT00820053牵头方II期2009-01 启动
  34. Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC已完成NCT00834158牵头方不分期2009-01 启动
  35. Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver Cancer已完成NCT00822562牵头方不分期2009-01 启动
  36. Cytoreductive Surgery and Transarterial Chemoembolization (TACE) Versus TACE for Hepatocellular Carcinoma已完成NCT00820157牵头方不分期2008-11 启动
  37. A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection已完成NCT00819650牵头方II期2008-12 启动
  38. Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection已完成NCT00825669牵头方不分期2008-12 启动
  39. A Trial of Complete Versus Selective HepaticVascular Clamping in Hepatectomy已完成NCT00851968牵头方不分期2008-12 启动
  40. Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels已完成NCT00814242牵头方II/III期2008-12 启动
  41. Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence已完成NCT00817895牵头方不分期2008-12 启动
  42. Efficacy and Significance of Antiviral Therapy for Unresectable Hepatitis B Virus-related Primary Liver Cancer已完成NCT00824707牵头方不分期2008-12 启动
  43. A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular Carcinoma已完成NCT00825474牵头方不分期2008-08 启动
  44. The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma已完成NCT00827554牵头方II/III期2008-12 启动
  45. Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion已完成NCT00826384牵头方I/II期2008-10 启动
  46. Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients已完成NCT00849264牵头方II期2008-12 启动
  47. Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH状态不明NCT02587884牵头方I期
  48. HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)状态不明NCT06210334牵头方(推断)II期2024-03 启动
  49. Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid进行中,不再招募NCT06699524牵头方(推断)2022-09 启动
  50. Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma状态不明NCT02632188牵头方(推断)I/II期2015-09 启动
  51. Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma状态不明NCT02638857牵头方(推断)I/II期2015-09 启动
  52. Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma状态不明NCT02632006牵头方(推断)I/II期2015-09 启动
  53. Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy状态不明NCT02399033牵头方(推断)IV期2014-06 启动
  54. A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma状态不明NCT02253511牵头方(推断)IV期2014-07 启动
  55. S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)状态不明NCT01533324牵头方(推断)II期2011-11 启动
  56. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion正在招募NCT07170345研究中心2025-09 启动
  57. 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness即将招募NCT07100236研究中心2025-08 启动
  58. Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China邀请入组NCT06712017研究中心2024-08 启动
  59. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  60. Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC已撤回NCT06361758研究中心II期2024-05 启动
  61. A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).已终止NCT05975645研究中心I期2023-08 启动
  62. Auxiliary Diagnosis of Liver Nodules Using cfDNA Whole-genome Signatures状态不明NCT05393102研究中心2022-05 启动
  63. Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma状态不明NCT05626985研究中心2022-10 启动
  64. Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma状态不明NCT05389527研究中心II期2022-09 启动
  65. Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer已撤回NCT05292443研究中心2021-12 启动
  66. A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs状态不明NCT04538313研究中心I/II期2020-08 启动
  67. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  68. YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)已完成NCT04000737研究中心II期2020-01 启动
  69. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  70. A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion状态不明NCT03971201研究中心II期2019-09 启动
  71. Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation状态不明NCT02631499研究中心IV期2015-12 启动
  72. The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma状态不明NCT01055743研究中心II期2009-08 启动
  73. Urea Cream Treatment Sorafenib-Associated HSFR in HCC已完成NCT01934829研究中心II期2009-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.06%。

牵头论文
6
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 2220232024: 0020242025: 222025

上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。

这些数字背后的记录
研究主题腹膜转移与晚期手术影像与人工智能
论文中的科室普外/肝胆胰外科病理/检验科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 112025

上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 17 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284研究中心III期2009-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 13 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Asia-Pacific consensus guidelines for endoscopic management of benign biliary strictures.2017Gastrointestinal endoscopy

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

海军军医大学第三附属医院(东方肝胆外科医院)

Eastern Hepatobiliary Surgery Hospital

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Eastern Hepatobiliary Surgery Hospital; Shanghai Eastern Hepatobiliary Surgery Hospital; Eastern Hepatobiliary Surgery Institute; Third Affiliated Hospital of Second Military Medical University; Third Affiliated Hospital of Naval Medical University; Eastern Hepatobiliary Surgery Hospital/Institute; Eastern Hepatobiliary Surgery Institute/Hospital; Eastern Hepatobiliary Hospital

提出更正下载数据